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ABSTRACT In estradiol 17β-d-glucuronide (E17G)–induced cholestasis, the canalicular hepa-
tocellular transporters bile salt export pump (Abcb11) and multidrug-resistance associated 
protein 2 (Abcc2) undergo endocytic internalization. cAMP stimulates the trafficking of trans-
porter-containing vesicles to the apical membrane and is able to prevent internalization of 
these transporters in estrogen-induced cholestasis. Hepatocyte levels of cAMP are regulated 
by hormones such as glucagon and adrenaline (via the β2 receptor). We analyzed the effects 
of glucagon and salbutamol (a β2 adrenergic agonist) on function and localization of Abcb11 
and Abcc2 in isolated rat hepatocyte couplets exposed to E17G and compared the mecha-
nistic bases of their effects. Glucagon and salbutamol partially prevented the impairment in 
Abcb11 and Abcc2 transport capacity. E17G also induced endocytic internalization of Abcb11 
and Abcc2, which partially colocalized with the endosomal marker Rab11a. This effect was 
completely prevented by salbutamol, whereas some transporter-containing vesicles remained 
internalized and mainly colocalizing with Rab11a in the perinuclear region after incubation 
with glucagon. Glucagon prevention was dependent on cAMP-dependent protein kinase 
(PKA) and independent of exchange proteins activated directly by cAMP (Epac) and microtu-
bules. In contrast, salbutamol prevention was PKA independent and Epac/MEK and microtu-
bule dependent. Anticholestatic effects of glucagon and salbutamol were additive in nature. 
Our results show that increases in cAMP could activate different anticholestatic signaling 
pathways, depending on the hormonal mediator involved.
INTRODUCTION
Bile secretion depends on the normal activity of ATP-dependent 
transporters belonging to the ABC superfamily located in the canali-
cular pole of the hepatocyte (Gatmaitan and Arias, 1995; Borst and 
Elferink, 2002). Hence alterations in their activity, localization, and/
or expression lead to secretory failure and cholestasis (Trauner et al., 
1999; Crocenzi et al., 2003a). Among the most relevant transporters 
involved in bile formation are the bile salt export pump (Abcb11, 
also named Bsep), which transports monoanionic bile salts, and the 
multidrug-resistance associated protein 2 (Abcc2, also named 
Mrp2), which transports glutathione and glutathione conjugates, as 
well as a wide variety of anionic compounds, including bipolar, sul-
fated, or glucuronidated bile salts and bilirubin monoglucuronides 
and diglucuronides (Gatmaitan and Arias, 1995; Borst and Elferink, 
2002). Bile salts and glutathione are chief determinants of the so-
called bile salt-dependent and bile salt-independent fractions of the 
bile flow, respectively (Esteller, 2008).
Studies in different models of experimental cholestasis of clin-
ical relevance, including estrogen-induced cholestasis, revealed a 
series of characteristic alterations in the localization of canalicular 
transporters (Dombrowski et al., 2000; Mottino et al., 2002; 
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Crocenzi et al., 2003a). This work demonstrated that, in cholestatic 
conditions, Abcb11 and Abcc2 left the canalicular membrane, un-
dergoing endocytic internalization into vesicular compartments. 
This phenomenon was systematically associated with a failure in 
the secretion of their specific substrates, pointing to a key role of 
this pathomechanism in the cholestatic process. The endocytic in-
ternalization of transporters in cholestasis can be counterbalanced, 
at least conceptually, by signaling molecules that stimulate routes 
of exocytic insertion, therefore modifying the internalization/inser-
tion balance toward the latter process. In addition, the exocytic 
reinsertion of the endocytosed transporters that spontaneously 
occurs after the initial cholestatic insult with estradiol 17β-d-
glucuronide (E17G; Crocenzi et al., 2003a) can be accelerated by 
these signaling molecules, thus providing a means to speed up 
recovery from cholestasis. A signaling mediator with these stimu-
latory properties is cAMP. This signaling messenger stimulates, in 
the liver, the traffic of hepatocellular transporters from its places of 
synthesis to the canalicular membrane in a microtubule-depen-
dent manner, as well as the fusion of transporter-containing vesi-
cles from the subapical compartment with the apical membrane 
(Roelofsen et al., 1998; Kipp and Arias, 2002). Our group demon-
strated that cAMP prevents the internalization and accelerates 
the reinsertion of ABC transporters in E17G-induced cholestasis 
(Mottino et al., 2002; Crocenzi et al., 2003a).
cAMP is the second messenger of a number of hormones that 
act at the hepatic level, such as glucagon (Glu), vasoactive intestinal 
peptide, and catecholamines (Steinberg et al., 2003). The potential 
therapeutic use of such hormones is, in addition, rationally justified 
by the fact that, in cholestasis, the hormonal mechanisms that lead 
to cAMP synthesis are diminished due to the altered expression of 
subunit α of small stimulatory G proteins (Bouscarel et al., 1998). 
Among the hormones with potential anticholestatic properties, Glu 
and adrenaline could represent the most appropriate ones. Glu is 
recognized for its capacity to promote bile flow (Branum et al., 1991) 
and to elevate cAMP levels in humans (Pecker et al., 1979). In addi-
tion, Glu is produced in the pancreas and delivered to portal circula-
tion, thus arriving at the liver in high levels before reaching systemic 
circulation. Adrenaline increases cAMP levels in liver by means of 
the β2 adrenergic receptor (Morgan et al., 1983) and shares with Glu 
some cAMP-dependent hormonal effects in this organ such as gly-
cogenolysis (Bollen et al., 1998). Consequently, any modification of 
the synthesis or release rate of these hormones is expected to have 
an important impact in the liver in terms of signaling.
Within the cell, adenylyl-cyclases, phosphodiesterases, and path-
way effectors are closely associated. Therefore, cAMP generation and 
degradation is compartmentalized, leading to the existence of local-
ized pools of the messenger. cAMP signaling can be regulated by the 
integration of all stimuli and cellular processes implied in this genera-
tion/degradation (Tasken and Aandahl, 2004). Experimental data 
confirm that passive diffusion of cAMP in the cytosol is substantially 
restricted, as shown by monitoring the spatial distribution of cAMP in 
single living cells and by more indirect in vitro approaches (Zaccolo 
et al., 2006). The local elevation of cAMP can trigger different path-
ways. Among them, two are known as effectors of cAMP in exocytosis 
processes: cAMP-dependent protein kinase (PKA) and exchange pro-
teins activated directly by cAMP (Epac; de Rooij et al., 1998; Seino 
and Shibasaki, 2005). The aim of the present work is to evaluate the 
capability of the cAMP-elevating hormones Glu and adrenaline to 
prevent E17G-induced cholestasis, using isolated rat hepatocyte cou-
plets, and to characterize the eventual mechanism of protection in 
term of the signaling pathway involved (PKA or Epac) and cytoskele-
tal requirements, including a systematic comparison of their effects.
RESULTS
Salbutamol and glucagon partially prevent E17G-induced 
impairment of canalicular secretory function in a 
concentration-dependent manner
To assess which concentrations of Glu and salbutamol (Sal; 
β2 adrenergic agonist) produce a maximal protective effect, we 
performed concentration–response studies with various concen-
trations of Glu (0.001–10 μM) and Sal (0.1–1000 μM). Both Glu and 
Sal partially prevented the effect of 50 μM E17G on canalicular 
vacuolar accumulation (cVA) of cholyl-lysylfluorescein (CLF) and 
glutathione methylfluorescein (GS-MF) transport throughout the 
range of concentrations evaluated. Glu concentrations higher than 
0.1 μM did not produce further protection; likewise, Sal preventive 
effect was maximal at the dose of 1 μM (Supplemental Figure S1). 
Hence the remaining experiments were performed using these 
concentrations.
To further characterize the preventive effect of these compounds, 
we carried out different concentration–response studies in which the 
concentration of E17G was modified in the presence of fixed con-
centrations of Sal or Glu (Figure 1). Curves were adjusted assuming 
that the parameter minimal effect (bottom) was equal to 0 and that 
the Hill slope coefficient was 1. As shown in Table 1, the IC50 of CLF 
and GS-MF accumulation induced by E17G was significantly in-
creased in the presence of Glu by 104 and 67%, respectively. More-
over, Glu prevented the maximal inhibition of GS-MF accumulation 
induced by E17G. Similarly, the hormone tended to decrease the 
maximal effect of the estrogen glucuronide on CLF accumulation, 
although this difference did not reach statistical significance. Sal also 
increased the IC50 of E17G in CLF and GS-MF accumulation (90 and 
100%, respectively). However, Sal did not alter the maximal effect of 
the estrogen metabolite.
Salbutamol and glucagon increase intracellular cAMP 
in isolated rat hepatocyte couplets
To determinate whether Sal and Glu increase cAMP levels, we incu-
bated isolated rat hepatocyte couplets (IRHCs) with these agonists 
in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX) and compared their effects with IRHC ex-
posed to IBMX alone (control). Glu and Sal significantly increased 
the intracellular levels of cAMP compared with control (control, 
2.62 ± 0.40; Glu, 25.79 ± 2.85*; Sal, 25.67 ± 0.91* pmol/105 IRHC; 
*different from control, p < 0.05, n = 3).
Glucagon but not salbutamol requires PKA activation 
for its preventive effect on E17G-induced impairment 
of canalicular secretory function
To study whether Sal or Glu protection is mediated by PKA, 
IRHCs were preincubated with two different PKA inhibitors. As 
shown in Figure 2, the ability of Glu to prevent the decrease in 
cVA of both CLF and GS-MF was blocked by the PKA inhibitors 
H89 and KT5720, indicating that this prevention requires PKA 
activation. It was surprising that when we analyzed Sal preven-
tion, its preventive capability was not blocked by these inhibi-
tors. These findings indicate that Sal’s preventive effect does not 
involve PKA activation. To confirm glucagon activation of PKA, 
kinase activity was evaluated by Western blot of the phosphory-
lated forms of PKA substrates (Figure 3). As previously reported, 
these immunoblots present several bands that could represent 
phosphorylated PKA substrates (Brennan et al., 2006; Lei 
et al., 2007). On the basis of their response to the PKA activator 
DBcAMP and PKA inhibitors, we analyzed two bands, of ∼25 and 
110 kDa. Glucagon increased the phosphorylation of these two 
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PKA substrates, and these increases were blocked by PKA 
inhibitors. These experiments also revealed that salbutamol ac-
tivates PKA, as previously demonstrated (Meja et al., 2004). 
8-(4-Chlorophenylthio)-2´-O-methyladenosine 3´,5´-cyclicmono-
phosphate (8-CPT-2´-O-Me-cAMP), a specific Epac activator, did 
not affect PKA phosphorylation.
Salbutamol but not glucagon requires microtubule integrity 
for its preventive effect on E17G-induced impairment 
of canalicular secretory function
To evaluate whether the protection afforded by these compounds 
occurs by a microtubule-dependent mechanism, we pretreated 
IRHC with colchicine, an inhibitor of microtubule polymerization. As 
shown in Figure 4, the preincubation with colchicine blocked the 
preventive effect of Sal on E17G impairment of Abcc2 and Abcb11 
function. On the other hand, colchicine did not cause inhibition in 
the protective effect of Glu. Therefore, unlike Sal, Glu exerts its pro-
tective effect by a microtubule-independent mechanism.
Glucagon and salbutamol have an additive protective effect 
in E17G-induced impairment of canalicular secretory function
To corroborate that Glu and Sal present different preventive mecha-
nisms, we coincubated IRHC with these compounds and evaluated 
cVA of CLF and GS-MF. Figure 5 shows that cells cotreated with Glu 
and Sal present an additive preventive effect on the impairment of 
the canalicular secretory function induced by E17G. Moreover, pre-
incubation with PKA inhibitors (KT5720 and H89) led to a partial in-
hibition of these additive effects, in accordance with the results 
shown in Figure 2.
Salbutamol activation of Epac pathway is necessary 
to prevent E17G-induced impairment in biliary 
secretory function
To evaluate whether Epac is implied in the protection by Sal of 
E17G-induced cholestatic effects, IRHC were incubated with 
CLF GS-MF
E17G 
alone
E17G + 
agent
E17G 
alone
E17G + 
agent
Glu
Maximal 
effect (%)
0 ± 2 8 ± 4 2 ± 2 22 ± 4a
IC50 (μM) 46 ± 1 94 ± 2a 51 ± 1 85 ± 2a
Sal
Maximal 
effect (%)
4 ± 3 6 ± 3 7 ± 4 6 ± 3
IC50 (μM) 69 ± 1 131 ± 1a 44 ± 2 88 ± 2a
Depicted in Figure 1. Data were analyzed with GraphPad Prism software, as-
suming the minimal effect of E17G (100% value) to be the cVA in control IRHCs.
aSignificantly different from the E17G-alone curve (p < 0.05).
TABLE 1: Estimates of the concentration–response curve parameters 
of E17G-induced impairment of canalicular secretory function in the 
presence of Glu (0.1 μM) and Sal (1 μM).
FIGuRE 1: Prevention by Glu (top) and Sal (bottom) of E17G-induced impairment of cVA of CLF (left) and GS-MF (right). 
IRHCs were preincubated with Glu (0.1 μM) or Sal (1 μM) for 15 min and then exposed to E17G (12.5–800 μM) for an 
additional 20 min. cVAs of CLF and GS-MF were calculated as the percentage of couplets displaying visible fluorescence 
in their canalicular vacuoles from a total of at least 200 couplets per preparation, referred to control cVA values. cVA 
control values were 75 ± 2% for CLF and 76 ± 2% for GS-MF. Data are expressed as mean ± SEM (n = 3).
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8-CPT-2´-O-Me-cAMP, a specific Epac agonist. Figure 6 shows that 
treatment with 8-CPT-2´-O-Me-cAMP partially prevented E17G-in-
duced alteration of Abcb11 and Abcc2 transport function in a 
microtubule-dependent manner. In addition, western blots of pMEK, 
an indicator of mitogen-activated protein kinase kinase (MEK) acti-
vation (Epac downstream; Bos et al., 2001), revealed that Sal and 
8-CPT-2´-O-Me-cAMP increased the amount of pMEK (Figure 7). 
The same figure shows that Glu does not affect pMEK levels with 
respect to control. To confirm the possible involvement of the Epac 
pathway in the beneficial effects of Sal, we used the specific MEK 
inhibitor PD98059. As shown in Figure 8, the ability of Sal and 8-CPT-
2´-O-Me-cAMP to prevent the decrease in cVA of both CLF and 
GS-MF induced by E17G was blocked by the MEK inhibitor, linking 
Sal prevention with Epac activation. When we analyzed the ability of 
Glu to prevent E17G effects, we found that its preventive capability 
was not blocked by this inhibitor. Furthermore, IRHC coincubated 
with 8-CPT-2´-O-Me-cAMP together with Sal or Glu (Figure 9) 
showed an additive protective effect only in 8-CPT-2´-O-Me-cAMP + 
Glu group but not in 8-CPT-2´-O-Me-cAMP + Sal group, corroborat-
ing that Sal, but not Glu, shares with 8-CPT-2´-O-Me-cAMP the pro-
tective mechanism triggered by activation of the Epac pathway.
Glucagon and salbutamol prevent E17G-induced retrieval 
of Abcb11 and Abcc2 by different mechanisms
Figures 10 and 11 illustrate the effect of the different treatments on 
Abcb11 and Abcc2 cellular localization in IRHC, respectively. F-Actin 
FIGuRE 2: Effect of the PKA inhibitors H-89 and KT5720 on the 
prevention by Glu and Sal of E17G-induced impairment of cVA 
of CLF (A) and GS-MF (B). Couplets pretreated for 15 min with H-89 
(200 nM), KT5720 (50 nM), or vehicle (DMSO) in controls were 
subsequently exposed to Glu or Sal for a further 15-min period and 
then exposed to E17G (50 μM) for an additional 20-min period. cVAs 
of CLF and GS-MF were calculated as the percentage of couplets 
displaying visible fluorescence in their canalicular vacuoles from a total 
of at least 200 couplets per preparation, referred to control cVA 
values. Control cVA values were 76 ± 1% for CLF and 76 ± 2% for 
GS-MF. Data are expressed as mean ± SEM (n = 3). aSignificantly 
different from control (p < 0.05). bSignificantly different from E17G 
and control (p < 0.05).
FIGuRE 3: Estimation of PKA activation by Glu and Sal. Isolated rat 
hepatocytes were incubated with DBcAMP (10 μM, positive control), 
Glu (0.1 μM), Sal (1 μM), and 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 
μM, negative control) in the presence or absence of PKA inhibitors 
(50 nM KT5720 or 200 nM H-89). PKA activity was determined by 
Western blot, using an antibody against phosphorylated PKA 
substrates. Two bands of 25 and 110 kDa were analyzed based on 
their response to DBcAMP and PKA inhibitors. Two exposure times 
were necessary to reveal these bands—a short exposure for the 
25-kDa band and a long exposure for the 110-kDa band. Differences 
in sample loading were corrected by the densitometric signal of the 
corresponding actin band. The ratio of each phosphorylated 
substrate/actin band density was compared with that of control bands 
(100%). Data are expressed as mean ± SEM (n = 3). aSignificantly 
different from control (p < 0.05). bSignificantly different from the 
agonist alone (p < 0.05).
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was stained and used to demarcate the limits of the canalicular 
membrane since actin network exhibits a predominant ring-shaped 
pericanalicular distribution (Roma et al., 1998). Confocal images 
show that, in control cells, Abcb11 and Abcc2 were mainly local-
ized within the actin pericanalicular ring space. IRHC treated with 
Glu, Sal, or 8-CPT-2´-O-Me-cAMP alone presented the same distri-
bution pattern (unpublished data). E17G induced redistribution of 
both Abcb11 and Abcc2 over a greater distance from the center of 
the canalicular vacuoles. Glu, Sal, and 8-CPT-2´-O-Me-cAMP pre-
vented E17G-induced retrieval of Abcb11 and Abcc2. However, 
some remnant transporter-containing vesicles remain visible in a 
deep compartment after preincubation with Glu of E17G-treated 
IRHC, which is not evident under Sal and 8-CPT-2´-O-Me-cAMP 
treatment (Figures 10 and 11A, arrowheads). Protection of canali-
cular transporters internalization by Glu, Sal, and 8-CPT-2´-O-
Me-cAMP was confirmed by densitometric analysis of the distribu-
tion of the transporters in the vicinity of the canalicular vacuole 
(Supplemental Figures S3 and s4). The mechanisms involved in 
their preventive effects were the same as those involved in the 
protection against the functional impairment of these transporters 
induced by E17G, that is, Glu-mediated prevention of canalicular 
transporter delocalization was blocked when cells were pretreated 
with the PKA inhibitors H89 and KT5720 (Figures 10 and 11B), 
whereas Sal- and 8-CPT-2´-O-Me-cAMP–mediated protection was 
abolished by colchicine, suggesting a microtubule-dependent 
protective effect (Figures 10 and 11, C and D) and PD98059, 
suggesting MEK1/2 involvement. Thus, these findings support the 
participation of the Epac–MEK1/2 pathway in the anticholestatic 
effects of Sal.
E17G-induced colocalization of canalicular transporters with 
endosomal marker Rab11a is prevented by Sal and only 
partially prevented by Glu
It was reported that canalicular Abcb11 and Abcc2, during their 
normal recycling between the canalicular membrane and the 
subapical compartment or under an endocytic stimulus, colocalize 
FIGuRE 4: (A) Representative confocal images of control-treated 
(left) and colchicine-treated (right) IRHCs stained for β-tubulin and 
actin (inset). (B, C) Effect of colchicine on Glu and Sal prevention of 
E17G-induced impairment of cVAs of CLF (B) and GS-MF (C). 
Couplets pretreated for 30 min with colchicine (Colch, 1 μM) or 
vehicle (DMSO) were subsequently exposed to Glu (0.1 μM) or Sal 
(1 μM) for 15 min and then exposed to E17G (50 μM) for an additional 
20 min. cVAs of CLF and GS-MF were calculated as the percentage of 
couplets displaying visible fluorescence in their canalicular vacuoles 
from a total of at least 200 couplets per preparation, referred to 
control cVA values. Control cVA values were 75 ± 3% for CLF and 
76 ± 1% for GS-MF. Data are expressed as mean ± SEM (n = 3). 
aSignificantly different from control (p < 0.05). bSignificantly different 
from E17G and control (p < 0.05).
FIGuRE 5: Effect of coincubation with Glu and Sal on E17G-induced 
impairment of canalicular vacuolar accumulations (cVAs) of CLF 
(A) and GS-MF (B). IRHCs were incubated with Glu (0.1 μM) and Sal 
(1 μM), either alone or together, for 15 min and then exposed to 
E17G (50 μM) for an additional 20 min. Finally cVAs of CLF and GS-MF 
were calculated as the percentage of couplets displaying visible 
fluorescence in their canalicular vacuoles from a total of at least 
200 couplets per preparation, referred to control cVA values. Control 
cVA values were 76 ± 3% for CLF and 75 ± 1% for GS-MF. Data are 
expressed as mean ± SEM (n = 3). aSignificantly different from control 
(p < 0.05). bSignificantly different from E17G and control (p < 0.05). 
cSignificantly different from E17G, E17G + Glu, E17G + Sal, E17G + 
Glu + Sal + H-89, and E17G + Glu + Sal + KT5720 (p < 0.05).
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intracellularly with the endosomal marker Rab11a (Wakabayashi 
et al., 2004; Wang et al., 2006). In line with this, Figure 12 shows that 
E17G induced delocalization of Abcb11 (top) and Abcc2 (bottom) 
to the inner part of the cell. Part of transporter-associated fluores-
cence colocalized with Rab11a in the perinuclear region (arrowheads 
in amplified images). Sal treatment led all transporters back to the 
canalicular domain. In turn, Glu treatment partially prevented 
the effects of E17G on canalicular transporters since part of those 
transporter-containing vesicles internalized by the estrogen re-
mained colocalized with Rab11a in the perinuclear region after Glu 
treatment (arrowheads in amplified images).
DISCUSSION
This study gives insight into the mechanism of prevention of E17G-
induced cholestasis afforded by cAMP and the role of different 
downstream pathways in the series of events leading to this 
prevention.
Both cAMP-elevating compounds analyzed—Glu and Sal—dis-
placed the E17G concentration–response curve of cVA of both 
Abcc2 and Abcb11 substrates to the right, indicating a partial 
protective effect of these compounds on the cholestatic failure in-
duced by E17G. However, Glu presented a clear tendency toward 
impeding the complete blockage of the canalicular transport func-
tion that occurs at high estrogen concentrations, although this was 
significant only for the transport of GS-MF. This could indicate that 
part of the transporters endocytosed by E17G are readily available 
to be reinserted by Glu (Figure 1, top). In turn, Sal does not prevent 
the E17G maximal effect (Figure 1, bottom), suggesting a different 
mechanism of action. Confocal images also suggest different mech-
anisms of action since Sal fully prevented transporter delocalization 
induced by E17G, whereas Glu relocalized a great part of delocal-
ized transporters but could not avoid that part of the transporters 
remaining in the perinuclear zone (Figures 10 and 11), mainly colo-
calizing with the endosomal marker Rab11a (Figure 12).
A detailed analysis of the results showed that Glu protection is 
carried out by PKA activation not requiring microtubule integrity, 
whereas Sal protection, surprisingly, did not require PKA activation 
but was dependent on microtubule integrity. Accordingly, protec-
tion afforded by Sal and Glu together presented an additive effect, 
corroborating the existence of independent mechanisms of protec-
tion. Moreover, we observed that activation of Epac pathway pre-
vented E17G-induced impairment of canalicular secretory function. 
Similar to Sal action, this prevention was microtubule dependent. 
Finally, inhibition of MEK, a kinase downstream of Epac, blocked 
Sal’s protective effect. All of these facts indicate that Sal mediates its 
beneficial effects by activating a cAMP-Epac signaling pathway, 
probably via MEK1 or 2. Further supporting this, coincubation with 
Sal and 8-CPT-2´-O-Me-cAMP, an Epac agonist, did not produce an 
additive protective effect, which points to a shared intracellular 
pathway. In contrast, Glu and 8-CPT-2´-O-Me-cAMP induced addi-
tive effects, giving additional evidence for the existence of different 
mechanisms of protection. It is worth noting that these results repre-
sent the first evidence that Epac activation could play a role in pro-
tection against E17G-induced cholestasis.
FIGuRE 6: Effect of colchicine on the prevention of E17G-induced 
impairment in the canalicular vacuolar accumulation (cVA) of CLF 
(A) and GS-MF (B) afforded by activation of the Epac pathway with 
8-CPT-2´-O-Me-cAMP. IRHCs were preincubated with colchicine for 
30 min and then with 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM) 
for a further 15 min and subsequently exposed to E17G (50 μM) 
for an additional 20 min. Finally, cVAs of CLF and GS-MF were 
calculated as the percentage of couplets displaying visible 
fluorescence in their canalicular vacuoles from a total of at least 
200 couplets per preparation, referred to control cVA values. 
Control cVA values were 74 ± 1% for CLF and 75 ± 2% for GS-MF. 
Data are expressed as mean ± SEM (n = 3). aSignificantly different 
from control (p < 0.05). bSignificantly different from E17G and 
control (p < 0.05).
FIGuRE 7: Estimation of MEK activation by salbutamol and 8-CPT-2´-
O-Me-cAMP. Isolated rat hepatocytes were incubated with Glu (0.1 
μM), Sal (1 μM), and 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM, 
positive control). MEK activity was determined by immunoblots, using 
an antibody against phosphorylated MEK1/2. A band at 45 kDa was 
detected. Differences in sample loading were corrected by the 
densitometric signal of the corresponding actin band. The ratio of 
each pMEK/actin band density was compared with the ratio of control 
bands (100%). Data are expressed as mean ± SEM (n = 3). 
aSignificantly different from control (p < 0.05).
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Previously, our group demonstrated that microtubule integrity 
is necessary for the recovery of bile secretion and the retargeting 
of the endocytosed transporters back to the canalicular membrane 
that spontaneously occurs after a single E17G insult (Mottino 
et al., 2005). In line with this, Roelofsen et al. (1998) showed that 
cAMP participate in the three steps of the reinsertion of Abcc2 fol-
lowing the redistribution that occurs after IRHC isolation, that is, 
the endocytosis from the basolateral plasma membrane where 
Abcc2 is initially redistributed, its transcytosis to the apical pole in 
a microtubule-dependent manner, and, finally, the fusion of trans-
porter-containing vesicles with the apical membrane in a microtu-
bule-independent manner. Although this approach differs from 
our cholestatic model in the cause of the transporter redistribution 
process and in the extent at which this redistribution occurs, the 
two last steps can, in principle, be applied to the spontaneous re-
insertion of transporters that occurs after E17G cholestasis. Our 
approach using different hormones that increase intracellular lev-
els of cAMP allowed us to discriminate different actions of this 
second messenger, depending on its different origins within the 
cell. cAMP intracellular distribution following Glu/Sal–induced syn-
thesis is compartmentalized in spatially restricted zones under-
neath the plasma membrane (Garcia et al., 2001; Tasken and Aan-
dahl, 2004), and Glu-associated cAMP seems to act only in the last 
step of fusion of subapical vesicles with the apical membrane, 
which is independent of microtubules but dependent on PKA ac-
tivity. In contrast, Sal seems to increase cAMP in the microdomain 
responsible for the microtubule-dependent trafficking of trans-
porter-containing vesicles from a deep vesicular domain to the im-
mediacies of the apical membrane, without the final intervention 
of the PKA-dependent fusion process. Lack of action of Glu on 
microtubule-dependent reinsertion of transporters may be the 
cause of the persistence of part of Abcb11 and Abcc2 colocalizing 
with Rab11a in the perinuclear zone.
The protection induced by Sal indicates that transporter-contain-
ing vesicles not only are transferred to the vicinity of the apical 
membrane, but also are fused to the membrane. This final fusion is, 
FIGuRE 8: Effect of MEK1/2 inhibitor PD98059 on Glu, Sal, and 
8-CPT-2´-O-Me-cAMP prevention of E17G-induced impairment of 
canalicular vacuolar accumulations (cVAs) of CLF (A) and GS-MF (B). 
Couplets pretreated for 15 min with PD98059 (PD, 1 μM) or vehicle 
(DMSO) were subsequently exposed to Glu (0.1 μM), Sal (1 μM), or 
8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM) for 15 min and then 
exposed to E17G (50 μM) for an additional 20 min. cVAs of CLF and 
GS-MF were calculated as the percentage of couplets displaying 
visible fluorescence in their canalicular vacuoles from a total of at least 
200 couplets per preparation, referred to control cVA values. Control 
cVA values were 75 ± 1% for CLF and 76 ± 2% for GS-MF. Data are 
expressed as mean ± SEM (n = 3). aSignificantly different from control 
(p < 0.05). bSignificantly different from E17G and control (p < 0.05).
FIGuRE 9: Effect of coincubation with Glu + 8-CPT-2´-O-Me-cAMP 
and Sal + 8-CPT-2´-O-Me-cAMP on E17G-induced impairment of cVA 
of CLF (A) and GS-MF (B). IRHCs were coincubated with Glu (0.1 μM) 
and 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM), or Sal (1 μM) and 
8-CPT-2´-O-Me-cAMP, for 15 min and then exposed to E17G (50 μM) 
for an additional 20 min. Finally cVAs of CLF and GS-MF were 
calculated as the percentage of couplets displaying visible 
fluorescence in their canalicular vacuoles from a total of at least 
200 couplets per preparation, referred to control cVA values. Control 
cVA values were 77 ± 3% for CLF and 74 ± 1% for GS-MF. Data are 
expressed as mean ± SEM (n = 3). aSignificantly different from control 
(p < 0.05). bSignificantly different from E17G and control (p < 0.05). 
cSignificantly different from E17G, E17G + Glu, and E17G + 8-CPT-
cAMP (p < 0.05).
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FIGuRE 10: Representative confocal images showing cellular distribution of Abcb11, actin, and merged images (with 
actin in red and Abcb11 in green) in IRHCs under different treatments. (A) Prevention by Glu (0.1 μM) and Sal (1 μM) of 
E17G (200 μM)-induced retrieval of Abcb11. Note that under control conditions Abcb11-associated fluorescence is 
mainly localized at the canalicular membrane in the area delimited by the pericanalicular actin ring. E17G induced a clear 
internalization of Abcb11-containing vesicles beyond the limits of the pericanalicular actin ring, a phenomenon 
significantly prevented by Glu and Sal. The arrowhead in the E17G + Glu group shows some transporter-containing 
vesicles that remain internalized in a deep intracellular compartment. (B) Preincubation with the PKA inhibitor H-89 
(200 nM) or KT5720 (KT, 50 nM) significantly inhibited the preventive effect of Glu on E17G-induced internalization of 
Abcb11. (C) Pretreatment of IRHC with the microtubule-disrupting agent colchicine (Colch, 1 μM), or the MEK1/2 
inhibitor PD98059 (PD, 1 μM) abolished the preventive effect of Sal on E17G-induced internalization of Abcb11. 
(D) Pretreatment of IRHC with 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM), an Epac agonist, also prevented 
delocalization of Abcb11 induced by E17G, a phenomenon also abolished by preincubation with Colch and PD. None of 
the treatments affected the normal distribution of actin, which showed a predominant pericanalicular distribution.
Volume 22 October 15, 2011 cAMP protection of estrogen cholestasis | 9 
FIGuRE 11: Representative confocal images showing cellular distribution of Abcc2, actin, and merged images (with 
actin in red and Abcc2 in green) in IRHCs under different treatments. (A) Prevention by Glu (0.1 μM) and Sal (1 μM) of 
E17G (200 μM)-induced retrieval of Abcc2. Note that under control conditions Abcc2-associated fluorescence is mainly 
localized at the canalicular membrane in the area delimited by the pericanalicular actin ring. E17G induced a clear 
internalization of Abcc2-containing vesicles beyond the limits of the pericanalicular actin ring, a phenomenon 
significantly prevented by Glu and Sal. The arrowhead in the E17G + Glu group shows some transporter-containing 
vesicles that remain internalized in a deep intracellular compartment. (B) Preincubation with the PKA inhibitor H-89 
(200 nM) or KT5720 (KT, 50 nM) significantly inhibited the preventive effect of Glu on E17G-induced internalization of 
Abcc2. (C) Pretreatment of IRHCs with the microtubule-disrupting agent colchicine (Colch, 1 μM) or the MEK1/2 
inhibitor PD98059 (PD, 1 μM) abolished the preventive effect of Sal on E17G-induced internalization of Abcc2. 
(D) Pretreatment of IRHCs with 8-CPT-2´-O-Me-cAMP (8-CPT-cAMP, 50 μM), an Epac agonist, also prevented 
delocalization of Abcc2 induced by E17G, a phenomenon also abolished by preincubation with Colch and PD. None of 
the treatments affected the normal distribution of actin, which showed a predominant pericanalicular distribution.
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FIGuRE 12: Representative confocal images showing cellular distribution of canalicular transporters, endosomal marker 
Rab11a, and merged images (with endosomal marker in red, canalicular transporter in green, and nuclei in blue) in 
IRHCs under the different treatments. (Top) Prevention by Glu (0.1 μM) and Sal (1 μM) of E17G (200 μM)-induced 
retrieval of Abcb11. (Bottom) Prevention by Glu (0.1 μM) and Sal (1 μM) of E17G (200 μM)-induced retrieval of Abcc2. 
Square demarcated zones are shown amplified below the corresponding microphotographs. E17G induced a clear 
internalization of transporter-containing vesicles beyond the canalicular region, reaching the perinuclear zone and 
partially colocalizing with Rab11a (arrowheads), a phenomenon significantly prevented by Glu and Sal. The E17G + Glu 
group shows some transporter-containing vesicles that remained mainly colocalizing with the endosomal marker Rab11a 
in a deep intracellular compartment (arrowheads).
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unlike that induced by Glu, PKA independent. This could indicate 
the existence of two pools of transporters ready to be inserted in the 
canalicular membrane with differential fusion mechanisms in terms 
of PKA requirements. In line with this, Kipp et al. (2001) postulated 
the existence of a pool of Abcb11 that depends on cAMP and an-
other pool that depends on bile salts. Our results suggest that both 
Abcb11 and Abcc2 endocytosed from the membrane can be readily 
reinserted by a PKA-dependent mechanism and that transporters 
derived from microtubular traffic are spontaneously fused to the 
membrane in a PKA-independent manner. Because Kipp et al. did 
not study the mechanism of vesicle fusion, it is impossible to associ-
ate PKA-dependent and PKA-independent pools with cAMP- and 
bile salt–dependent pools with certainty.
Regarding E17G-induced cholestasis, the present data demon-
strate that E17G administration leads to transporter relocalization at 
two different levels—one next to the apical membrane, which can 
be reverted by Glu, and another one to a deeper compartment, 
which needs microtubule integrity to be reverted. This reversion 
could depend on reinsertion of previously deinserted transporters 
and/or on the transfer of newly synthesized transporters from the 
Golgi apparatus (Kipp and Arias, 2000). Experimental data support 
the former explanation since transporters that were delocalized by 
E17G colocalized with Rab11a, and those transporters that failed to 
be relocalized by glucagon also mainly colocalized with Rab11a. A 
tentative model to explain the differential actions of Sal and Glu is 
depicted in Figure 13.
Potential targets of activated PKA include the actin cytoskele-
ton and the transporters themselves. Transporter phosphorylation 
cannot be ruled out, but no evidence for such a process exists. 
Some pieces of evidence point to actin reorganization as a poten-
tial target. cAMP greatly accelerated the reorganization of F-actin 
in IRHCs after the disarrangement induced by cell isolation, and 
this closely paralleled the reinsertion of canalicular transporters 
back to the canalicular domain; conversely, maneuvers retarding 
actin reorganization (e.g., protein kinase C activation, Ca2+ seques-
tration) delayed transporter retargeting (Roma et al., 2000). In line 
with this, cAMP protects against oxidative stress–induced altera-
tion in actin cytoskeleton via a PKA-dependent mechanism (Perez 
et al., 2006), which suggests a role for the kinase in actin organiza-
tion in hepatocytes. cAMP also stimulated the microfilament-me-
diated fusion of the basolateral bile salt transporter Na+–tauro-
cholate cotransporting polypeptide with its membrane domain 
(Dranoff et al., 1999).
On the other hand, Epac actions could be involved in micro-
tubule assembly. Sehrawat et al. (2008) found that Epac1 activa-
tion is involved in increasing the length of microtubules from hu-
man umbilical vein endothelial cells. Mei and Cheng (2005) found 
similar results, and they concluded that Epac binds to tubulin and 
its activation is necessary for microtubule formation. In view of 
this evidence, our results suggest that cAMP activation of Epac 
prevents cholestasis by acting at the level of microtubules, prob-
ably increasing microtubule assembly necessary for the traffic of 
transporter-containing vesicles that were deeply endocytosed by 
E17G action. Epac involvement in the final PKA-independent ve-
sicular fusion could not be ruled out based on our results.
Summarizing, we can say that Glu favors the reinsertion of sub-
apical transporters that are endocytosed by E17G through a mecha-
nism that involves both microtubule-independent trafficking and 
activation of PKA. In contrast, Sal stimulates selectively a microtu-
bule-dependent pathway, which is PKA independent and depends 
on Epac activation. On the basis of evidence on trafficking mecha-
nisms, we propose that cAMP derived from Sal modulates the long-
range trafficking of transporter-containing vesicles, whereas cAMP 
derived from Glu participates in the microfilament-mediated fusion 
of these vesicles with the apical membrane. Because endocytic in-
ternalization of canalicular transporters relevant to bile formation is 
a common feature of most forms of cholestasis (Roma et al., 2008) 
and probably a main pathomechanism, a better understanding of 
the cAMP-dependent beneficial signaling pathways, such as that 
provided by this work, may help to develop new therapeutic strate-
gies aimed at affording appropriate transporter localization after a 
cholestatic insult.
MATERIALS AND METHODS
Materials
E17G, Leibovitz-15 (L-15) culture medium, collagenase type A from 
Clostridium histolyticum, colchicine, albumin, paraformaldehyde, 
Triton X-100, 88-CPT-2´-O-Me-cAMP, adrenaline, isoproterenol, 
salbutamol, fentolamine, butoxamine, propranolol, atenolol, 
PD98059, N6,2´-O-dibutyryladenosine 3´:5´ cyclical monophos-
phate (DBcAMP), and dimethyl sulfoxide (DMSO) were from Sigma-
Aldrich (St. Louis, MO). Glucagon was from Eli Lilly (Indianapolis, IN). 
5-Chloromethylfluorescein diacetate (CMFDA) was from Life Tech-
nologies Corporation (Carlsbad, CA). Cholyl-lysylfluorescein (CLF) 
was kindly provided by Charles O. Mills (Birmingham, United King-
dom). KT5720 and N-[2-(methylamino) ethyl]-5-isoquinolinesulfon-
amide (H-89) were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA). All other chemicals were of the highest grade available.
Isolation and culture of rat hepatocyte couplets 
To obtain a preparation enriched in IRHCs, livers from adult, female 
Wistar rats weighing 250–300 g and bred in our animal house as 
FIGuRE 13: Proposed model for cAMP-dependent transporter 
reinsertion after their endocytic internalization induced by E17G. The 
cholestatic estrogen glucuronide produces deinsertion of canalicular 
transporters to a subapical vesicle pool and to a deeper endocytic 
compartment. Glu mediates the reinsertion of subapical transporters 
via a PKA-dependent mechanism. On the other hand, Sal, via 
Epac–MEK activation, promotes the microtubule-dependent 
trafficking of transporter-containing vesicles toward the canalicular 
pole from a deep endocytic pool, the final fusion of subapical vesicles 
with the apical membrane being independent of PKA.
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described (Crocenzi et al., 2003b), were perfused under urethane 
anesthesia (1 g/kg intraperitoneally) according to the two-step col-
lagenase perfusion procedure and were further enriched by centrif-
ugal elutriation (Gautam et al., 1987; Wilton et al., 1991. The final 
preparation contained 70–80% of IRHCs with viability >95%, as as-
sessed by the trypan blue exclusion test. After isolation, IRHCs were 
plated onto 24-well plastic plates at a density of 0.5 × 105 U/ml in 
L-15 culture medium, and they were cultured for 5 h to allow the 
restoration of couplet polarity.
IRHC treatments
To determine which adrenergic receptor is involved in the preven-
tive effect of adrenaline, in preliminary studies cells were incubated 
with different specific adrenergic agonists (1 μM adrenaline, 1 μM 
isoproterenol; 10 μM Sal and 30 μM fentolamine) for 15 min before 
addition of E17G (50 μM), and thus maintained throughout the 
period of exposure to E17G (20 min). To discriminate which sub-
type of receptor β is involved in the prevention, IRHCs were prein-
cubated with different specific β-receptor antagonists (1 μM pro-
pranolol; 1 μM atenolol and 5 μM butoxamine) before the addition 
of the adrenergic agonists. Results from these ancillary studies 
showed protective effect of adrenaline, isoproterenol, and Sal and 
no protection of fentolamine for Abcb11 and Abcc2 function. This 
protection was reverted by butoxamine and propranolol but not 
by atenolol, indicating that protective effect was mediated by β2 
receptors (Supplemental Figure S3). Hence further studies con-
cerning adrenergic protection were carried out using Sal, a β2 
agonist.
To evaluate the protective effects of Glu and Sal, IRHCs were in-
cubated for 15 min with Glu (0.001–10 μM) or Sal (0.1–1000 μM) and 
then exposed to DMSO (control group) or various concentrations of 
E17G (12.5–800 μM) for 20 min in the presence of Glu or Sal.
The possible involvement of PKA in the protective effect of Glu 
and Sal against E17G-induced secretory failure was evaluated by 
incubating the cells for 15 min with the PKA inhibitor KT5720 
(50 nM) or H-89 (200 nM) (Kimura and Ogihara, 1997), followed by 
incubation with 0.1 μM Glu or 1 μM Sal 15 min before the addition 
of E17G (50 μM, 20 min) to the culture medium.
The possible participation of the Epac pathway in the preventive 
effect of the studied compounds was evaluated by treating IRHCs 
for 15 min with a specific Epac agonist (50 μM 8-CPT-2´-O-Me-
cAMP) in the presence or absence of 0.1 μM Glu and 1 μM Sal 
15 min before addition of E17G (50 μM, 20 min). To confirm Epac 
participation in Sal effects, we incubated IRHC for 15 min with a 
specific MEK (Epac downstream) inhibitor PD98059 (1 μM) in the 
presence of Glu, Sal, and 8-CPT-2´-O-Me-cAMP 15 min before addi-
tion of E17G (50 μM, 20 min).
To assess the possible involvement of microtubules in the actions 
of Sal, Glu, or 8-CPT-2´-O-Me-cAMP, IRHCs were preincubated for 
30 min with the inhibitor of microtubule polymerization colchicine 
(1 μM) (Mottino et al., 2005). Then IRHCs were preincubated with 
8-CPT-2´-O-Me-cAMP, Glu, or Sal before the addition of E17G, as 
described earlier.
Assessment of Abcb11 and Abcc2 secretory function 
and localization in IRHCs
The transport function of Abcb11 and Abcc2 was evaluated by 
analyzing the canalicular vacuolar accumulation of the fluorescent 
substrates CLF and GS-MF, respectively (Roma et al., 2000; Wang 
et al., 2002). CLF is a bile salt analogue transported selectively by 
Abcb11 (Mills et al., 1999), whereas CMFDA is a lipophilic com-
pound taken up by passive diffusion across the basolateral mem-
[AQ 1]
[AQ 2]
brane and converted into GS-MF by the sequential action of intra-
cellular esterases and glutathione S-transferases. For transport 
studies, cells were washed twice with L-15 and exposed to 2 μM 
CLF (Crocenzi et al., 2003b; Roma et al., 2003) or 2.5 μM CMFDA 
(Roelofsen et al., 1998; Roma et al., 2000) for 15 min. Finally, cells 
were washed twice with L-15, and canalicular transport activity for 
both substrates was assessed by fluorescence microscopy (Roma 
et al., 2000) under an inverted microscope (Axiovert 25, Zeiss, Göt-
tingen, Germany). Images were captured with a digital camera 
(Q-Color5; Olympus America, Center Valley, PA), and the cVA of 
the fluorescent substrates was determined as the percentage of 
IRHCs in the images displaying visible green fluorescence in their 
canalicular vacuoles from a total analysis of at least 200 couplets 
per preparation.
To evaluate the intracellular distribution of Abcb11 and Abcc2, 
IRHCs were fixed and stained as previously reported (Roma et al., 
2000). The E17G concentration used in these experiments 
(200 μM) was higher than that used in functional experiments to 
render transporter retrieval more evident. After treatments, IRHCs 
were fixed with 4% paraformaldehyde in phosphate-buffered sa-
line (PBS) and permeabilized with PBS–Triton X-100 2%–bovine 
serum albumin (BSA). Then cells were incubated with a polyclonal 
antibody against mouse Abcb11 (1:100, 2 h) (Kamiya Biomedical, 
Seattle, WA) or a monoclonal antibody against human ABCC2 
(1:100, 2 h; M2III-6; Alexis Biochemicals, San Diego, CA), followed 
by incubation with Cy2-conjugated donkey anti–immunoglobulin 
G (IgG; 1:200) for 40 min or fluorescein isothiocyanate (FITC)–
labeled goat anti–mouse IgG (1:200, 1 h; Zymed, San Francisco, 
CA). To delimit the canaliculi, F-actin was stained by coincubating 
cells with Alexa Fluor 568 phalloidin (Invitrogen, Carlsbad CA) 
(1:100, 1 h). In colocalization studies of Abcc2 and Abcb11 with 
Rab11a, after fixation, transporters were stained using the primary 
and secondary antibodies just described. Rab11a was detected 
by using two different specific antibodies: a mouse monoclonal to 
Rab11a antibody (1:100, 2 h; Abcam, Cambridge, MA) for cola-
beling with Abcb11 and a rabbit polyclonal to Rab11a antibody 
(1:100, 2 h; Invitrogen) for colabeling with Abcc2, followed by in-
cubation with a Cy3-conjugated donkey anti–mouse IgG and a 
Cy3-conjugated goat anti–rabbit IgG (1:200 1 h; Jackson Immu-
noResearch Laboratory, West Grove, PA), respectively. Cellular 
nuclei were stained by incubating during 10 min with 1.5 μM 
4,6-diamidino-2-phenylindol (Invitrogen). Finally, cells were 
mounted and examined with a Nikon C1 Plus confocal laser scan-
ning microscope attached to a Nikon TE-2000 inverted micro-
scope (Nikon, Tokyo, Japan).
Assessment of microtubule status in IRHCs
Colchicine specificity on microtubule integrity was confirmed by im-
munofluorescence after treatment of cells with DMSO (control) or 
colchicine for 30 min. Then cells were washed three times with PBS, 
fixed (4% paraformaldehyde, 0.1% Triton X-100, 80 mM potassium 
1,4- piperazinediethanesulfonate, pH 7.2, 1 mM ethylene glycol tet-
raacetic acid, 1 mM MgSO4, 30% glycerol) for 20 min at room tem-
perature (Larocca et al., 2004) and permeabilized with PBS–Triton 
X-100 2%–BSA, and incubated with a monoclonal antibody against 
mouse β-tubulin (Sigma-Aldrich; 1:100, 2 h). To delimit the canali-
culi, actin network was stained by coincubating cells with Alexa 
Fluor 568 phalloidin (Invitrogen; 1:100). Finally, cells were incubated 
for 40 min with FITC-labeled goat anti–mouse IgG (1:100, 1 h; 
Zymed). Cells were then mounted and examined with a Nikon C1 
Plus confocal laser scanning microscope, attached to a Nikon TE-
2000 inverted microscope.
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Assessment of intracellular cAMP levels in IRHCs
In the IRHC model, couplets were plated in 35-mm plastic plates 
covered with collagen (0.5 × 105 U/ml) and cultured for 5 h at 
37°C to allow restoration of couplet polarity. Subsequently, IRHCs 
were preincubated with the phosphodiesterase inhibitor IBMX 
(0.8 mM) for 5 min and then incubated with DMSO (control), Glu 
(0.1 μM), or Sal (1 μM) for 15 min. Reaction was stopped by the 
addition of ice-cold ethanol for 20 min. Then ethanol was evapo-
rated, and the residue was resuspended for cAMP determination, 
which was carried out by competition of [3H]cAMP for carbon/
dextran–immobilized PKA, as previously described (Davio et al., 
1995; Sabbatini et al., 2003). Results are expressed as pmol/105 
IRHC.
Immunoblot analysis of PKA substrate 
phosphorylation status
The phosphorylation status of PKA substrates was analyzed to 
evaluate PKA activation by hormonal modulators, as well as to test 
the efficacy of the PKA inhibitors used in this study. Briefly, isolated 
hepatocytes were obtained by collagenase perfusion as previously 
described (Garcia et al., 2001) and cultured in 3-cm, collagen-
coated Petri dishes at a density of 2 × 106 cells/ml. After a 24-h 
culture period, cells were preincubated for 5 min with IBMX 
(0.8 mM) and then exposed to DBcAMP (10 μM, positive control), 
Glu (0.1 μM), Sal (1 μM), and 8-CPT-2´-O-Me-cAMP (50 μM) in the 
presence or absence of the PKA inhibitor KT5720 (50 nM) or H-89 
(200 nM). After treatments, cells were washed with cold PBS and 
finally resuspended in a cellular lysis buffer containing Protease 
Inhibitor Cocktail (Sigma-Aldrich) and phosphatase inhibitors 
(Phosphatase Inhibitor Cocktail 3 [Sigma-Aldrich], 1 mM NaF, and 
1 mM Na3VO4). Aliquots containing an equivalent total protein 
content, as determined by the Lowry procedure with BSA as the 
standard (Lowry et al., 1951), were subjected to SDS/12% PAGE. 
Separated proteins were electrotransferred to Immobilon-P mem-
branes and probed with an anti–Phospho-(Ser/Thr) PKA Substrate 
Antibody (Cell Signaling Technology, Danvers, MA; 1:1000) over-
night. After the use of a donkey anti–rabbit IgG secondary anti-
body (1:5000), membranes were revealed using standard chemilu-
minescence protocols. Bands were quantified by densitometry 
with ImageJ 1.44p software (National Institutes of Health, Bethesda, 
MD). The membranes were then stripped and reprobed with an 
anti-actin antibody (Invitrogen; 1:5000).
Immunoblot analysis of MEK phosphorylation
Activation of Epac was confirmed by Western blot analysis of the 
phosphorylation status of MEK, a downstream Epac effector, in pri-
mary cultured hepatocytes. Briefly, after a 24-h culture period, cells 
were exposed to DMSO (control), Glu (0.1 μM), Sal (1 μM), and 
8-CPT-2′-O-Me-cAMP (50 μM) for 15 min, then washed with cold 
PBS, and finally resuspended in a cellular lysis buffer containing 
Protease Inhibitor Cocktail (Sigma-Aldrich) and phosphatase in-
hibitors (Phosphatase Inhibitor Cocktail 3 [Sigma-Aldrich], 1 mM 
NaF, and 1 mM Na3VO4). Aliquots containing an equivalent total 
protein content were subjected to SDS/12% PAGE. Separated pro-
teins were electrotransferred to Immobilon-P membranes and 
probed with an anti-Phospho-MEK1/2 (Ser-217/221) Antibody 
(Cell Signaling Technology; 1:1000) overnight. After the use of a 
donkey anti–mouse IgG secondary antibody (1:5000), membranes 
were revealed using standard chemiluminescence protocols. 
Bands were quantified by densitometry with ImageJ 1.44p soft-
ware. The membranes were then stripped and reprobed with an 
anti-actin antibody (1:5000).
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